Chiusura precedente | 3,2500 |
Aperto | 3,2700 |
Denaro | 2,9900 x 400 |
Domanda | 3,0600 x 100 |
Min-Max giorno | 3,0100 - 3,2700 |
Intervallo di 52 settimane | 1,5740 - 8,1940 |
Volume | |
Media Volume | 186.784 |
Capitalizzazione | 130,801M |
Beta (mensile su 5 anni) | 0,62 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,1000 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 12,50 |
Six abstracts, spanning Werewolf’s PREDATOR™ platform and INDUKINE™ pipeline, accepted for poster presentations at SITC annual meetingCompany to present interim first-in-human clinical data from initial monotherapy dose-escalation cohorts in ongoing Phase 1/1b study of WTX-124 WATERTOWN, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated t
Virtual event to be held on Monday, September 18, 2023, at 10:00 am ETWATERTOWN, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will host a virtual R&D Event on Monday, September 18, 2023, at 10:00 am ET. The event will fe
WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will participate in the following upcoming investor conferences in the month of September: H.C. Wainwright Annual Global Investor ConferenceDate: Monday, Se